We postulate that combining Aurora-A kinase inhibitors with IL-16 antibodies will be a useful therapeutic strategy for cancer patients with high tumor-intrinsic Aurora-A expression and high lymphocyte infiltration. The gene discussed is IL16; the disease is cancer.